Targets › OPN4
1 program from 1 company in 1 trial: 1 Phase 4; Neurology; next expected readout Dec 2026.
G protein-coupled photoreceptor that signals through the G(q/11) family of G proteins in response to light in intrinsically photosensitive retinal ganglion cells (ipRGCs) (By similarity). Can also activate other G proteins, including G(i/o) and G(s), depending on the cell type, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent signaling. (UniProt, Q9UHM6)
Open in Phaseline: the race on OPN4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Blue light exposure Photoentrainment via intrinsically photosensitive retinal ganglion cells | OPN4 | Phase 4 | Ischemic Stroke, Acute | Dec 2026 |
Ischemic Stroke, Acute (1)
small molecule (1)
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.